Ashvattha Therapeutics

Ashvattha Therapeutics is an innovative biopharmaceutical company focused on Hydroxyl Dendrimer Therapeutics (HDTs). HDTs exhibit excellent cellular targeting for diseases and can be administered systemically through oral or injectable methods while selectively targeting reactive cells in diseased tissues, providing localized and sustained effects that benefit patients. Additionally, Hydroxyl Dendrimers (HD) can penetrate tissue barriers to treat various diseases. With good safety profiles, minimal off-target toxicity, and suitability for large-scale production.